CervoMed Inc. 8-K

What Happened
CervoMed Inc. (CRVO) filed a Form 8-K on April 7, 2026, under Item 7.01 (Regulation FD disclosure) to announce that company representatives will present key aspects of its neflamapimod clinical program at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, GA on April 7, 2026. The company attached a press release as Exhibit 99.1.

Key Details

• Event date & place: April 7, 2026 — 2026 Lewy Body Dementia Association Annual Meeting, Atlanta, GA.
• Topic: Presentation of key aspects of CervoMed’s neflamapimod clinical program.
• SEC filing: Form 8-K filed April 7, 2026, with the press release included as Exhibit 99.1 (Item 7.01 disclosure).
• Other: Item 9.01 notes exhibits filed with the report (standard exhibit attachment).

Why It Matters
This filing is a Regulation FD disclosure informing the market that CervoMed will publicly discuss its neflamapimod program at a disease-focused scientific meeting. For investors, the announcement increases the program’s visibility and signals where updated clinical information or corporate messaging may be shared. The 8-K does not report new clinical data or financial results — it documents that the company will present information at the April 7, 2026 meeting and provides the press release as the source.